Update on Repros’ Androxal – Analyst Blog

By | September 14, 2012

Repros Therapeutics Inc. ( RPRX ) recently provided an update on its phase III program, Androxal indicated for the treatment of secondary hypogonadism. The company has started randomizing

Visit site:
Update on Repros’ Androxal – Analyst Blog